Last reviewed · How we verify

NCT03317691

The ALERT-Pilot Study

Status unknown Last updated 14 November 2017
What this trial tests

trial testing electrocardiogram diagnosed by artificial intelligence in Myocardial Infarction, Acute in 2,000 participants. Status unknown.

Timeline
20 October 2017
Primary endpoint
15 October 2018
1 November 2018

Quick facts

Lead sponsorShanghai 10th People's Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment2,000
Start date20 October 2017
Primary completion15 October 2018
Estimated completion1 November 2018
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai 10th People's Hospital

Who can join

18 and older, any sex, with Myocardial Infarction, Acute or Artificial Intelligence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the algorithm of artificial intelligent to diagnose myocardial infarction through prior surgery Electrocardiogram was established. The accuracy of using artificial intelligent to diagnose acute ST-segment elevation myocardial infarction and judge criminal vascular was evaluated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Surgical data science - from concepts toward clinical translation.
    Maier-Hein L, Eisenmann M, Sarikaya D, März K, et al · · 2022 · cited 158× · PMID 34879287 · DOI 10.1016/j.media.2021.102306

Verify or expand the search:

Other recruiting trials for Myocardial Infarction, Acute

Currently open trials in the same condition.

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03317691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing